Nurix Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Nurix Therapeutics (Nasdaq: NRIX) announced that Arthur T. Sands, M.D., Ph.D., will participate in two significant conferences in September 2022. The presentations include a Fireside chat at the Wells Fargo Healthcare Conference on September 7 from 3:45 to 4:15 p.m. ET, and another at the Baird 2022 Global Healthcare Conference on September 13 from 10:50 to 11:20 a.m. ET. These events will be webcast live, with recordings available for approximately 30 days. Nurix specializes in targeted protein modulation for treating cancer.

SAN FRANCISCO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in the following conferences in September:

• Wells Fargo Healthcare Conference
  Fireside chat: Wednesday, September 7 at 3:45 – 4:15 p.m. ET
• Baird 2022 Global Healthcare Conference
  Fireside chat: Tuesday, September 13 at 10:50 – 11:20 a.m. ET

The events will be webcast live and may be accessed via a link in the Investors section of the Nurix website under Events and Presentations. An archived copy of the webcast will be available on the Nurix website for approximately 30 days after the event.

About Nurix

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule and cell therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com/.

Contacts:

Investors
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com

Media
Brett Whelan
LifeSci Communications
bwhelan@lifescicomms.com

FAQ

What is the schedule for Nurix Therapeutics' upcoming conferences in September 2022?

Nurix Therapeutics will participate in the Wells Fargo Healthcare Conference on September 7 from 3:45 to 4:15 p.m. ET and the Baird 2022 Global Healthcare Conference on September 13 from 10:50 to 11:20 a.m. ET.

How can I access the webcasts of Nurix Therapeutics' conference presentations?

The webcasts for Nurix Therapeutics' conference presentations can be accessed via a link in the Investors section of the Nurix website and will be available for about 30 days after the events.

What technologies does Nurix Therapeutics focus on for drug development?

Nurix Therapeutics focuses on targeted protein modulation using E3 ligases and proprietary DNA-encoded libraries to develop small molecule and cell therapies.

What is the primary goal of Nurix Therapeutics' drug discovery approach?

Nurix's drug discovery approach aims to modulate cellular protein levels by harnessing or inhibiting E3 ligases to selectively modify protein levels within cells.

Where is Nurix Therapeutics headquartered?

Nurix Therapeutics is headquartered in San Francisco, California.